Q-omics provides the consensus-scored KDR profile across patient tissues and cancer cell-line models. KDR expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KDR is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, KDR RNA expression shows 19,381 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, KIRP, and THYM as cancer lineages where KDR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KDR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KDR survival associations across molecular data types. KDR RNA expression shows survival associations in the most cancer types (25), followed by mutation status (9) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KDR RNA expression–survival associations across cancer types. High KDR expression shows unfavorable associations in UVM, KIRP and BLCA, but favorable associations in KIRC, HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KDR RNA expression.
This table summarizes KDR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for KDR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KDR shows lower tumor expression in KIRP, KICH, LUSC, LUAD and THCA and higher tumor expression in KIRC. The KIRP box plot shows higher KDR RNA expression in normal versus tumor tissue (log2 FC = −2.576, t-test p < 0.001).
This table shows molecular features associated with KDR in patient tissues and cancer cell lines. In patient samples, KDR shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, KDR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LARGE_INTESTINE.
